Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
Status:
Unknown status
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum dose that is safely tolerated of the
experimental drug Rhenium Re 188 P2045. This will be done by first treating patients at
relatively low doses of Rhenium Re 188 P2045, observing them closely to assure that there are
no bad side effects, then increasing the dose when we are confident that it is safe to do so.